Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TPA 023 is a selective agonist of GABAA α2/α3 subtype (Kis = 0.19 - 0.41 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 372.00 | |
5 mg | In stock | $ 788.00 | |
10 mg | In stock | $ 1,080.00 | |
25 mg | In stock | $ 1,630.00 | |
50 mg | In stock | $ 2,180.00 | |
100 mg | In stock | $ 2,970.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 685.00 |
Description | TPA 023 is a selective agonist of GABAA α2/α3 subtype (Kis = 0.19 - 0.41 nM). |
Targets&IC50 | GABAA:(ki)0.19-0.41 nM |
In vivo | TPA023 (0.7, 2.0, and 5 mg/kg, p.o.) blocks ketamine's cognitive-impairing ability but does not influence the behavioral symptoms of rhesus monkeys[1]. In rats, TPA023 (0.42 mg/kg; oral) displays good receptor occupancy and results in 50% occupancy of rat brain GABAA receptors, with the corresponding plasma concentration being 25 ng/mL. TPA023 (3 mg/kg p.o. in 0.5% methylcellulose) shows anxiolytic-like effect on rats. TPA023(10 mg/kg i.p.) is efficacious in the mouse pentylenetetrazole-induced seizure model, providing full seizure protection(84% occupancy), with the ED50 of 0.19-0.41 nM[2]. |
Molecular Weight | 395.43 |
Formula | C20H22FN7O |
CAS No. | 252977-51-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (126.44 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TPA 023 252977-51-8 Membrane transporter/Ion channel Neuroscience GABA Receptor inhibit γ-Aminobutyric acid Receptor Inhibitor Gamma-aminobutyric acid Receptor TPA-023 TPA023 inhibitor